drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Autologous, lentiviral-transduced dual STAR-T cell therapy targeting BCMA and LILRB4; synthetic antigen receptors engage BCMA and LILRB4 to signal via native TCR/CD3, activating T-cell cytotoxicity. Dose: 1E6–1E7 cells/kg IV; repeat dosing allowed.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express dual synthetic antigen receptors that bind BCMA and LILRB4 and signal through the native TCR/CD3 complex. Target engagement activates T-cell cytotoxicity and cytokine release against BCMA+ myeloma cells and LILRB4+ cells in the tumor milieu, aiming to enhance efficacy and reduce antigen escape/immunosuppression.
drug_name
YTS104
nct_id_drug_ref
NCT05913804